Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Femtogenix
Harpenden, Hertfordshire, United Kingdomfemtogenix.com ↗
- Ownership
- Private
- Employees
- ~25
- Development stage
- Other
01
Overview
Femtogenix develops DNA-interactive payloads (pyridinobenzodiazepine mono‑alkylators such as FGX20‑75 and FGX2‑62) for antibody-drug conjugates; published data show high in vitro potency, strong in vivo efficacy and improved tolerability in xenograft models, but there are no disclosed clinical-stage assets yet.[2][4][7]
- Therapeutic areas
- OncologyHematology
- Modalities
- Antibody-drug conjugateSmall molecule
- Industry
- Biotech
02
Partnerships
Iksuda Therapeutics (use of Femtogenix FGX2‑62 payload in IKS-01 ADC)[4]
Beyond the preview
Go deeper on Femtogenix.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Femtogenix.